219 related articles for article (PubMed ID: 29103756)
1. Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma.
Faden DL; Thomas S; Cantalupo PG; Agrawal N; Myers J; DeRisi J
Oral Oncol; 2017 Nov; 74():8-14. PubMed ID: 29103756
[TBL] [Abstract][Full Text] [Related]
2. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
[TBL] [Abstract][Full Text] [Related]
3. Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
Messerschmidt C; Obermayer B; Klinghammer K; Ochsenreither S; Treue D; Stenzinger A; Glimm H; Fröhling S; Kindler T; Brandts CH; Schulze-Osthoff K; Weichert W; Tinhofer I; Klauschen F; Keilholz U; Beule D; Rieke DT
Int J Cancer; 2020 Oct; 147(8):2293-2302. PubMed ID: 32468570
[TBL] [Abstract][Full Text] [Related]
4. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
Cho RJ; Alexandrov LB; den Breems NY; Atanasova VS; Farshchian M; Purdom E; Nguyen TN; Coarfa C; Rajapakshe K; Prisco M; Sahu J; Tassone P; Greenawalt EJ; Collisson EA; Wu W; Yao H; Su X; Guttmann-Gruber C; Hofbauer JP; Hashmi R; Fuentes I; Benz SC; Golovato J; Ehli EA; Davis CM; Davies GE; Covington KR; Murrell DF; Salas-Alanis JC; Palisson F; Bruckner AL; Robinson W; Has C; Bruckner-Tuderman L; Titeux M; Jonkman MF; Rashidghamat E; Lwin SM; Mellerio JE; McGrath JA; Bauer JW; Hovnanian A; Tsai KY; South AP
Sci Transl Med; 2018 Aug; 10(455):. PubMed ID: 30135250
[TBL] [Abstract][Full Text] [Related]
5. APOBEC Mutagenesis Is Concordant between Tumor and Viral Genomes in HPV-Positive Head and Neck Squamous Cell Carcinoma.
Faden DL; Kuhs KAL; Lin M; Langenbucher A; Pinheiro M; Yeager M; Cullen M; Boland JF; Steinberg M; Bass S; Lewis JS; Lawrence MS; Ferris RL; Mirabello L
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452530
[TBL] [Abstract][Full Text] [Related]
6. HPV Meets APOBEC: New Players in Head and Neck Cancer.
Riva G; Albano C; Gugliesi F; Pasquero S; Pacheco SFC; Pecorari G; Landolfo S; Biolatti M; Dell'Oste V
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573337
[TBL] [Abstract][Full Text] [Related]
7. Elevated APOBEC mutational signatures implicate chronic injury in etiology of an aggressive head-and-neck squamous cell carcinoma: a case report.
Patel J; den Breems NY; Tuluc M; Johnson J; Curry JM; South AP; Cho RJ
J Med Case Rep; 2021 Apr; 15(1):252. PubMed ID: 33926553
[TBL] [Abstract][Full Text] [Related]
8. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
9. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development.
Henderson S; Chakravarthy A; Su X; Boshoff C; Fenton TR
Cell Rep; 2014 Jun; 7(6):1833-41. PubMed ID: 24910434
[TBL] [Abstract][Full Text] [Related]
10. APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma.
Cannataro VL; Gaffney SG; Sasaki T; Issaeva N; Grewal NKS; Grandis JR; Yarbrough WG; Burtness B; Anderson KS; Townsend JP
Oncogene; 2019 May; 38(18):3475-3487. PubMed ID: 30647454
[TBL] [Abstract][Full Text] [Related]
11. A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC).
Wintergerst L; Selmansberger M; Maihoefer C; Schüttrumpf L; Walch A; Wilke C; Pitea A; Woischke C; Baumeister P; Kirchner T; Belka C; Ganswindt U; Zitzelsberger H; Unger K; Hess J
Mol Oncol; 2018 Dec; 12(12):2085-2101. PubMed ID: 30259648
[TBL] [Abstract][Full Text] [Related]
12. Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50.
Chandrasekharappa SC; Chinn SB; Donovan FX; Chowdhury NI; Kamat A; Adeyemo AA; Thomas JW; Vemulapalli M; Hussey CS; Reid HH; Mullikin JC; Wei Q; Sturgis EM
Cancer; 2017 Oct; 123(20):3943-3954. PubMed ID: 28678401
[TBL] [Abstract][Full Text] [Related]
13. Antitumor miR-150-5p and miR-150-3p inhibit cancer cell aggressiveness by targeting SPOCK1 in head and neck squamous cell carcinoma.
Koshizuka K; Hanazawa T; Kikkawa N; Katada K; Okato A; Arai T; Idichi T; Osako Y; Okamoto Y; Seki N
Auris Nasus Larynx; 2018 Aug; 45(4):854-865. PubMed ID: 29233721
[TBL] [Abstract][Full Text] [Related]
14. Expressed HNSCC variants by HPV-status in a well-characterized Michigan cohort.
Qin T; Zhang Y; Zarins KR; Jones TR; Virani S; Peterson LA; McHugh JB; Chepeha D; Wolf GT; Rozek LS; Sartor MA
Sci Rep; 2018 Jul; 8(1):11458. PubMed ID: 30061624
[TBL] [Abstract][Full Text] [Related]
15. The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma.
Yarbrough WG
Laryngoscope; 2002 Dec; 112(12):2114-28. PubMed ID: 12461329
[TBL] [Abstract][Full Text] [Related]
16. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
17. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
[TBL] [Abstract][Full Text] [Related]
18. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis of the microRNA-mRNA response to radiochemotherapy in primary head and neck squamous cell carcinoma cells.
Summerer I; Hess J; Pitea A; Unger K; Hieber L; Selmansberger M; Lauber K; Zitzelsberger H
BMC Genomics; 2015 Sep; 16(1):654. PubMed ID: 26328888
[TBL] [Abstract][Full Text] [Related]
20. [Mutation signatures in head and neck squamous cell carcinoma : Pathogenesis and therapeutic potential].
Plath M; Hess J; Zaoui K
HNO; 2020 Dec; 68(12):922-926. PubMed ID: 33044581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
